首页> 外文期刊>Alternatives to laboratory animals: ATLA >Three-dimensional co-culture of primary human liver cells in bioreactors for in vitro drug studies: effects of the initial cell quality on the long-term maintenance of hepatocyte-specific functions.
【24h】

Three-dimensional co-culture of primary human liver cells in bioreactors for in vitro drug studies: effects of the initial cell quality on the long-term maintenance of hepatocyte-specific functions.

机译:在生物反应器中原代人肝细胞的三维共培养用于体外药物研究:初始细胞质量对肝细胞特异性功能的长期维持的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

In vitro culture models that employ human liver cells could be potent tools for predictive studies on drug toxicity and metabolism in the pharmaceutical industry. A bioreactor culture model was developed that permits the three-dimensional co-culture of liver cells under continuous medium perfusion with decentralised mass exchange and integral oxygenation. We tested the ability of the system to support the long-term maintenance and differentiation of primary human liver cells. The effects of the initial cell quality were investigated by comparing cultures from resected, non-preserved liver with cultures from liver graft tissue damaged by long-term preservation. In cultures originating from non-preserved liver, protein and urea synthesis, glucose metabolism, and cytochrome (CYP450) activities were stable over the 2-week culture period, with maximal activities at the end of the first week in culture. Enzyme induction led to increased 7-ethoxyresorufin O-deethylase activities of up to 20 times the basal value. In cultures from preservation-damaged liver, recovery of metabolic activities was detected during bioreactor culture. After two weeks, most biochemical parameters approached those of cultures from non-preserved human liver. Light microscopy demonstrated the three-dimensional reorganisation of hepatocytes and non-parenchymal cells in co-culture. Long-term maintenance, and even the regeneration of specific functional activities of human liver cells, can be achieved in the bioreactor. This could facilitate the introduction into the pharmaceutical industry of in vitro drug testing with primary human liver cells.
机译:采用人肝细胞的体外培养模型可能是预测制药行业药物毒性和新陈代谢的有效工具。建立了一种生物反应器培养模型,该模型允许在连续的培养基灌流,分散的质量交换和整体氧合作用下进行肝细胞的三维共培养。我们测试了该系统支持人类原代肝细胞长期维持和分化的能力。通过比较未切除的未保存肝脏的培养物和长期保存受损的肝移植组织的培养物,研究了初始细胞质量的影响。在源自未保存的肝脏的培养物中,蛋白质和尿素合成,葡萄糖代谢和细胞色素(CYP450)活性在2周的培养期内保持稳定,在培养的第一周结束时活性最高。酶诱导导致增加的7-乙氧基间苯二酚O-脱乙基酶活性高达基础值的20倍。在保存受损的肝脏培养物中,在生物反应器培养过程中检测到代谢活性的恢复。两周后,大多数生化参数接近未保存的人类肝脏培养物。光学显微镜证实了在共培养中肝细胞和非实质细胞的三维重组。在生物反应器中可以实现长期维护,甚至可以再生人肝细胞的特定功能活性。这可能有助于将原代人肝细胞进行体外药物测试引入制药行业。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号